DETECTION OF ASPERGILLUS GALACTOMANNAN BY ENZYME IMMUNOABSORBENT ASSAY IN RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE STUDY

Background. Invasive aspergillosis (IA) has become the leading infectious cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This is partially because of the lack of a sensitive, specific, and noninvasive diagnostic test. New diagnostic tests for IA, such as the detection of Aspergillus galactomannan antigen (AGA) by sandwich enzyme-linked immunoabsorbent assay (ELISA), have recently been described. This study validates the usefulness of this diagnostic tool in the allo-HSCT setting. Methods. From January 1999 to January 2001, all consecutive adult patients undergoing allo-HSCT were prospectively studied with a galactomannan antigenemia assay (ELISA test) twice weekly from admission until death or discharge, and weekly afterward if the patient received immunosuppressive therapy. Proven, probable, and possible IA were defined according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. Results. During the 2 years of study, 74 patients underwent an allo-HSCT. A total of 832 serum samples were collected. According to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria, it was ascertained that 66 patients did not fulfill any criteria of IA, 2 patients were classified with possible IA, 5 patients were classified with probable IA, and 1 patient was classified with proven IA. Fourteen samples were positive for AGA, all from patients with IA. The sensitivity and specificity of the test were 75% and 100%, respectively. The positive predictive and negative predictive values were 100% and 97%, respectively. Conclusions. In this study, AGA detection was clearly related to IA. Although the ELISA test did not have any role in the anticipation of the diagnosis, it clarifies the diagnosis of IA in allo-HSCT.

[1]  T. Pumarola,et al.  Pulmonary Infiltrates in Immunosuppressed Patients: Analysis of a Diagnostic Protocol , 2002, Journal of Clinical Microbiology.

[2]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  T. Pumarola,et al.  Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures , 2001, Thorax.

[4]  J. Verhaegen,et al.  Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. , 2001, Blood.

[5]  E. Jantunen,et al.  Diagnostic aspects of invasive Aspergillus infections in allogeneic BMT recipients , 2000, Bone Marrow Transplantation.

[6]  J. Bourhis,et al.  Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. , 2000, The hematology journal : the official journal of the European Haematology Association.

[7]  G. Verhoef,et al.  Autopsy-Controlled Prospective Evaluation of Serial Screening for Circulating Galactomannan by a Sandwich Enzyme-Linked Immunosorbent Assay for Hematological Patients at Risk for Invasive Aspergillosis , 1999, Journal of Clinical Microbiology.

[8]  Sumio Kawamura,et al.  Comparison between PCR and Detection of Antigen in Sera for Diagnosis of Pulmonary Aspergillosis , 1999, Journal of Clinical Microbiology.

[9]  M. Richardson,et al.  Diagnosis and prevention of fungal infection in the immunocompromized patient. , 1998, Blood reviews.

[10]  J. Dimmock,et al.  In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone. , 1998, The Journal of antimicrobial chemotherapy.

[11]  R Sylvester,et al.  An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. , 1998, The Journal of infection.

[12]  C. Rieux,et al.  Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  E. Anaissie,et al.  Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  C. Viscoli,et al.  Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients , 1998, Bone Marrow Transplantation.

[15]  D. Stevens,et al.  Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. , 1997, Archives of internal medicine.

[16]  W. Leisenring,et al.  Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.

[17]  E. Jantunen,et al.  Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients , 1997, Bone Marrow Transplantation.

[18]  J. Meis,et al.  Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan , 1997, Journal of clinical microbiology.

[19]  A. Bernard,et al.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Denning Therapeutic outcome in invasive aspergillosis. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Latgé,et al.  Chemical and immunological characterization of the extracellular galactomannan of Aspergillus fumigatus , 1994, Infection and immunity.

[22]  V. Morrison,et al.  Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. , 1994, The American journal of medicine.

[23]  H. Prentice,et al.  Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  F. Derouin,et al.  Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. , 1993, Bone marrow transplantation.

[25]  Dirk,et al.  Rat monoclonal antibodies against Aspergillus galactomannan , 1992, Infection and immunity.

[26]  M. Rinaldi Problems in the diagnosis of invasive fungal diseases. , 1991, Reviews of infectious diseases.

[27]  T. Rogers,et al.  Value of antigen detection in predicting invasive pulmonary aspergillosis , 1990, The Lancet.

[28]  J. Wingard,et al.  Aspergillus infections in bone marrow transplant recipients. , 1987, Bone marrow transplantation.

[29]  V. Yu,et al.  Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year prospective study. , 1986, The American journal of medicine.